12-Hydroxy-5,8,10,14-eicosatetraenoic Acid

Subscribe to Selected New Research on 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid

102 relevant articles (1 outcomes, 4 trials/studies) found for this Bio-Agent

Description: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)

Also Known As:

12 S Hydroxyeicosatetraenoic Acid; Acid, 12-S-Hydroxyeicosatetraenoic; 12-HETE; 12-R-HETE; 12-S-HETE; 12-S-Hydroxyeicosatetraenoic Acid

Relationship Network

Bio-Agent Context: Research Results

Lipids: 13338

Fatty Acids: 4674

Unsaturated Fatty Acids: 2228

Eicosanoids: 1157

Arachidonic Acids: 78

Hydroxyeicosatetraenoic Acids: 135

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: 102

12,20-dihydroxy-5,8,10,14-eicosatetraenoic acid: 1

12,13-dihydroxy-5,8,10,14-eicosatetraenoic acid

Arachidonic Acids: 78

Hydroxyeicosatetraenoic Acids: 135

12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: 102

12,20-dihydroxy-5,8,10,14-eicosatetraenoic acid: 1

12,13-dihydroxy-5,8,10,14-eicosatetraenoic acid

Experts

1.	Kerr, Mary E: 1 article (06/2005)
2.	Reynolds, Robert B: 1 article (06/2005)
3.	Yonas, Howard: 1 article (06/2005)
4.	Poloyac, Samuel M: 1 article (06/2005)

Related Diseases

1.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2005 - "We showed that a 12-LO inhibitor, cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate (CDC) inhibited 12/15-LO activity in vivo and assessed the efficacy of another 12/15-LO inhibitor, N-benzyl-N-hydroxy-5-phenylpentamidine (BHPP), to diminish urinary 12-HETE and ameliorate diabetic nephropathy (DN) over 4 months" Order ALL the reference details at left...
2.	Anoxia (Hypoxia) 07/01/2000 - "Culture in hypoxia further increased intracellular 12-HETE threefold but had no additional effect on 12-HETrE" 07/01/2000 - "Hypoxia did not significantly increase extracellular 12-HETE or 12-HETrE; however, it caused more than 90% inhibition of PGE2 synthesis" 06/01/1993 - "Production of HETE was greatly increased at five hours of reoxygenation after 45 minutes of hypoxia [5-HETE = 12.0(SEM 0.5), 12-HETE = 23.6(1.1) ng.mg-1 protein]" 06/01/1986 - "Under hypoxia, verapamil decreased significantly 12-HETE and X production by fibroblasts (P less than 0.01 and P less than 0.05), whereas the synthesis in myocytes was not changed" 04/01/1998 - "In additional studies, we found that 12-HETE enhanced hypoxia-induced sickle-red-cell-endothelial adherence, and that this effect was mediated by potentiation of agonist-induced upregulation of the expression of the mRNA for vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells" Order ALL the reference details at left...
3.	Hyperplasia 11/01/2000 - "These results suggested the possible involvement of 12-HETE with the intimal hyperplasia under PR conditions." 11/01/2000 - "In the in vivo study in the PR group, the intimal hyperplasia and the plasma 12-HETE levels in the OPC-29030 group were significantly inhibited, compared with those of the control group" 11/01/2000 - "The mechanism of reducing the intimal hyperplasia may be that OPC-29030 inhibited 12-HETE production, which did not inhibit proliferation while inhibiting migration of the smooth muscle cell" 02/01/1987 - "In epidermis, LTB4 and 12-HETE caused some spongiosis as well as hyperplasia and increased tritiated thymidine autoradiographic labeling index" 01/01/2007 - "In addition, treatment of HaCaT cells with the 12-lipoxygenase metabolite 12 (S)-hydroxyeicosatetraenoic acid (12(S)-HETE) directly stimulated DNA synthesis and mitogenesis, and injection of insulin-like growth factor-II into the skin of hairless mice induced epidermal hyperplasia" Order ALL the reference details at left...
4.	Nephritis 08/25/1986 - "12-HETE synthesis is markedly increased in glomeruli from rats with nephrotoxic serum nephritis and leukotriene B4 synthesis in glomeruli from rats with cationic bovine gamma-globulin-induced glomerulonephritis" 11/01/1999 - "In this study we assessed the effect of a TxA2 synthase inhibitor, Dazmegrel, and a TxA2 receptor antagonist, SQ-29 548, on glomerular PGE2, LTB4, and 12-HETE synthesis in a model of mesangial nephritis induced in the rat by the administration of a monoclonal antibody against the Thy 1.1 antigen of rat mesangial cells" Order ALL the reference details at left...
5.	Brain Injuries (Brain Injury) 01/01/1989 - "The purpose of this study was to determine whether experimental fluid percussion brain injury in cats is associated with increased systemic levels of prostaglandins and the lipoxygenase product, 12-HETE" 01/01/1989 - "Increased plasma PGE2, 6-keto-PGF1 alpha, and 12-HETE levels following experimental concussive brain injury." Order ALL the reference details at left...

Related Drugs and Biologics

1.	4- (3- (biotinylaminohexamethylenaminocarbonyl)propanoylaminomethyl)- 2- methyl- 1,3- dithiolane- 2- yl- (Ala(7))phalloidin
2.	Leukotriene B4
3.	Lipoxygenase (Lipoxygenase-1)
4.	Dinoprostone (PGE2)
5.	Messenger RNA (mRNA)
6.	Prostaglandins
7.	OPC 29030
8.	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
9.	Thy-1 Antigens (Antigens, Thy 1)
10.	dazmegrel

Related Therapies and Procedures

1.	Ligation

Best Treatments:
Research Summary Report
on Diabetic Nephropathies

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 258 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>